Most Read Articles
24 Aug 2020
Colchicine, which is used to treat gout and other inflammatory disorders, appears to improve survival rate in patients with COVID-19 as compared with standard of care, as shown in a study.
Audrey Abella, Yesterday
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
20 Aug 2020
The use of proton pump inhibitors (PPIs) confers no risk increase for contracting SARS-CoV-2 infection, although PPI users with COVID-19 are likely to have severe outcomes, a study has found.

Product Highlight - Dupixent

16 Sep 2020
First and Only Biologic Therapy that specifically targets IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation (including Atopic Dermatitis and Asthma)1,2

Now locally approved for:

- Adult & adolescent (aged 12-17) patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy1
- An add-on maintenance treatment for patients (12+ years) with inadequately controlled severe asthma with type 2 inflammation1


References:
1. DUPIXENT Summary of Product Characteristics. May 2020.
2. Gandhi NA et al. Nature Rev Drug Disc 2016; 15: 35–50.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
24 Aug 2020
Colchicine, which is used to treat gout and other inflammatory disorders, appears to improve survival rate in patients with COVID-19 as compared with standard of care, as shown in a study.
Audrey Abella, Yesterday
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
20 Aug 2020
The use of proton pump inhibitors (PPIs) confers no risk increase for contracting SARS-CoV-2 infection, although PPI users with COVID-19 are likely to have severe outcomes, a study has found.